Trust And Talent In A Start-Up: A Two-Way Street
Rutger Zietsma, founder of Manus Neurodynamica and one of In Vivo's Rising Leaders of 2022, explains how his prior work guided his journey into executorship, and the issues of trust and talent in a start-up environment.
You may also be interested in...
Minute Insight: First Live Images Of Alpha-Synuclein Raise Hope For Improved Neurological Diagnostics
Advancements in imaging technology may bring medtech and pharma closer together and lead to better drugs for neurological conditions.
Medtech Insight spoke to Rutger Zietsma, Manus Neurodynamica’ CEO, to learn about the next commercial steps for the company's Neuromotor Pen for differential diagnosis of neuromotor impairment.
Manus Neurodynamica intends to launch a pen, which provides early and accurate diagnosis of Parkinson’s disease, to the UK and Benelux markets and has £5m in funding to date.